Dr. Ornstein on efficacy and safety of sacituzumab govitecan for urothelial cancer

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) for patients with urothelial cancer. The ADC is FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.